AliveCor Launches KardiaComplete to Help Reduce the Rising Health and Economic Costs of Heart Disease

AliveCor today announced the launch of KardiaComplete, a comprehensive heart health enterprise solution designed to drive improved health outcomes and reduce the cost of cardiac care.

The service will be available to people diagnosed with hypertension and arrhythmias, like atrial fibrillation, through their self-insured employers, health insurance plans and health systems.

KardiaComplete also addresses the urgent need to democratize heart care as the United States faces a significant cardiologist shortage.1 By leveraging data from best-in-class cardiac monitoring solutions – AliveCor’s KardiaMobile 6L, the #1 doctor-recommended personal ECG, and Omron’s Evolv, the #1 doctor and pharmacist-recommended blood pressure cuff – KardiaComplete meets people’s need for coaching and care in the moments that matter.

“KardiaComplete goes beyond short-term monitoring and education to offer payers and employers a more robust solution to manage patient care and drive lasting results,” said Priya Abani, Chief Executive Officer, AliveCor. “We have brought our deep heritage in AI and user-friendly devices and services to invent a single virtual disease management program that can augment existing programs and streamline patient care.”

Fueled by AliveCor’s AI-powered connected devices and services, KardiaComplete’s specialized live and digital heart health coaching helps address these conditions by offering lifestyle management tools that promote heart-healthy diet, movement, stress management and healthy sleep. In addition, a nationwide affiliated cardiologist care team co-manages patients with their primary care physicians utilizing evidence-based medication recommendations to help improve clinical outcomes.

KardiaComplete also offers support from a virtual assistant and personalized analyses of heart data to empower people living with heart conditions to better manage their health. Together, these features are designed to improve patient outcomes and reduce spending. In a modeled claims analysis of eligible commercial health plan members with hypertension and/or atrial fibrillation, KardiaComplete saved an estimated $160 per enrollee per month after one year by saving on acute events and disease progression.2

“Reducing the cost of heart care requires not only addressing established disease but also reducing the risk of disease progression that can lead to even greater downstream economic impacts,” said Archana Dubey, MD, Chief Clinical Officer, AliveCor. “By making it easier for people to take positive steps earlier in their journey, KardiaComplete aims to help those with early disease prevent further disease progression, and those with established disease to contain cardiovascular damage that can lead to stroke, congestive heart failure and other serious conditions.”

AliveCor plans to expand its future KardiaComplete offerings to people living with other serious heart conditions, such as heart failure and coronary artery disease.

SourceAliveCor

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”